MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

319.58

01-November-24 15:59:58

15 minutes delayed

Stocks

+60.24

+23.23%

Today's range

262.85 - 321.19

ISIN

N/A

Source

NASDAQ

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

18 Mar 2024 23:58:56 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Proposed Public Offering

18 Mar 2024 16:04:05 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

14 Mar 2024 16:15:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 Mar 2024 16:05:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

28 Feb 2024 07:01:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

28 Feb 2024 07:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

21 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

08 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 Feb 2024 16:05:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team

29 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

04 Jan 2024 08:00:01 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 16:30:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 Dec 2023 16:30:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

27 Nov 2023 16:30:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

21 Nov 2023 08:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

15 Nov 2023 16:45:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

10 Nov 2023 08:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

10 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.